Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ELUTIA INC. (ELUT)

Elutia Q3 2026 sales rise 20% to $1.1 million; continuing-operations loss widens

Mixed Impact 3 of 5 earnings Written later

Elutia reported third-quarter 2026 net sales of $1.1 million, up 20.4% from $0.9 million a year earlier. Its net loss narrowed to $1.3 million from $3.9 million, but that improvement came from $5.2 million of income from discontinued operations, while the loss from continuing operations widened to $6.5 million from $1.0 million. The company also said it received $26 million in funding in 2026 and plans to submit NXT-41x to the FDA in the fourth quarter of 2026.

Key points

  • Net sales were $1.1 million versus $0.9 million, an increase of 20.4%; cardiovascular sales grew 20%.
  • Net loss from continuing operations was $6.5 million versus $1.0 million; net loss was $1.3 million versus $3.9 million.
  • Income from discontinued operations was $5.2 million versus a loss of $2.8 million a year earlier.
  • Cash and cash equivalents were $29.1 million at September 30, 2026, excluding an $8 million Boston Scientific holdback received October 1, 2026.

The filing

CompanyELUTIA INC. (ELUT)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:05 PM ET
Accession number0001104659-26-123316

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.